386 filings
Page 3 of 20
NT 10-K
xwpzbtbm
28 Sep 21
Notice of late annual filing
4:31pm
8-K
im1oy o6w
21 Sep 21
Significantly Improved Safety Profile and Metabolism of Remdesivir Observed
11:25am
8-K
mqefb6pnb
15 Sep 21
NanoViricides Completes Licensing for Coronavirus Field which Includes Current COVID-19 Drug Development
4:36pm
SC 13G/A
iz23uz4zqt6s07wu9
16 Feb 21
NANOVIRICIDES / CVI Investments ownership change
9:47am
SC 13G/A
ffo8v yns0y
12 Feb 21
NANOVIRICIDES / Altium Capital Management ownership change
12:00am
SC 13G/A
koio 1gqszg
26 Jan 21
NANOVIRICIDES / Empery Asset Management ownership change
11:04am
SC 13G/A
leagf 5iy8zkl
4 Jan 21
NANOVIRICIDES / SABBY MANAGEMENT ownership change
11:44am
8-K
kdbhb1rlxjdq8bf
10 Dec 20
Submission of Matters to a Vote of Security Holders
4:30pm
424B5
13jjymtaxa 2ac40a
3 Dec 20
Prospectus supplement for primary offering
4:30pm
8-K
p4e a6l71z
19 Nov 20
NanoViricides Strengthens its Board of Directors with Addition of Industry Veteran Brian Zucker, CPA
4:53pm
NT 10-K
aqmtfe
28 Sep 20
Notice of late annual filing
4:30pm
8-K
wd31vtx91io
4 Sep 20
NanoViricides is Developing Drugs Against SARS-CoV-2 with an Integrated Approach to Combat COVID-19, as Reported at The LD 500 Virtual Conference
4:05pm
8-K
xnpf8qxj89twjb m77m7
3 Aug 20
Entry into a Material Definitive Agreement
5:19pm
424B5
08pnxq66q 8wvb3
31 Jul 20
Prospectus supplement for primary offering
5:29pm